31.95p-0.80 (-2.44%)20 Dec 2024, 16:30
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Futura Medical PLC Fundamentals

Company NameFutura Medical PLCLast Updated2024-12-20
IndustryBiotechnologySectorHealthcare
Shares in Issue303.704 mMarket Cap£97.03 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.2122Cash Equity Ratio0.5020
Quick Ratio3.3226Current Ratio3.75
Price To Book Value12.4224ROCE0

Futura Medical PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Futura Medical PLC Company Financials

Assets202320222021
Tangible Assets£2.48 m£1.16 m£442,657.00
Intangible Assets000
Investments000
Total Fixed Assets£2.48 m£1.16 m£442,657.00
Stocks£339.0000
Debtors£1.15 m£70,114.00£7,547.00
Cash & Equivalents£7.71 m£4.03 m£10.37 m
Other Assets000
Total Assets£11.82 m£6.47 m£11.80 m
Liabilities202320222021
Creditors within 1 year£6.34 m£1.75 m£2.08 m
Creditors after 1 year000
Other Liabilities000
Total Liabilities£6.34 m£1.75 m£2.08 m
Net assets£5.48 m£4.72 m£9.72 m
Equity202320222021
Called up share capital£602,812.00£576,093.00£574,302.00
Share Premium£71.07 m£66.55 m£66.38 m
Profit / Loss-£6.89 m-£6.87 m-£5.87 m
Other Equity£5.48 m£4.72 m£9.72 m
Preference & Minorities000
Total Capital Employed£5.48 m£4.72 m£9.72 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.21221.21221.2122
Cash / Equity0.50200.50200.5020
EPS-£0.02-£0.02-£0.02
Cash Flow202320222021
Cash from operating activities£570,253.00-£5.78 m-£3.87 m
Cashflow before financing£5.12 m-£5.61 m£9.77 m
Increase in Cash£3.69 m-£6.35 m£9.35 m
Income202320222021
Turnover£3.10 m00
Cost of sales£1.33 m00
Gross Profit£1.77 m00
Operating Profit-£6.96 m-£6.87 m-£5.87 m
Pre-Tax profit-£6.89 m-£6.87 m-£5.87 m

Futura Medical PLC Company Background

SectorHealthcare
ActivitiesFutura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives a majority of its revenue from the United Kingdom and the European Union.
Latest Interim Date10 Sep 2024
Latest Fiscal Year End Date10 Apr 2024

Futura Medical PLC Directors

AppointedNamePosition
2024-01-17Mr. Jeffrey Robert NeedhamNon-Executive Director,Chairman
2023-07-18Mr. John Milne ClarkeNon-Executive Director,Chairman
2016-03-31Ms. Lisa Arnold Non-Executive Director
2012-02-01Dr. William Duncan PotterExecutive Director,Chairman
2024-01-17Mr. Andrew Vaughan UnittNon-Executive Director,Senior Independent Director
2024-09-13Mr. James Henry BarderExecutive Director,Chief Executive
2021-12-29Mr. Jonathan David Freeman Non-Executive Director,Senior Independent Director
2015-03-28Mr. David Bryn DaviesExecutive Director,Chief Development Officer
2018-04-09Mr. Derek Adrian MartinExecutive Director,Finance Director and Company Secretary
2011-08-09Mr. Anthony Louis Clayden BSc,FCA,MSIExecutive Director,Finance Director and Company Secretary
2024-09-13Mr. Kenneth William JamesExecutive Director,Head of RandD
2024-04-29Ms. Angela HildrethExecutive Director,Finance Director, Chief Operating Officer and Company Secretary

Futura Medical PLC Contact Details

Company NameFutura Medical PLC
Address40 Occam Road, Surrey Technology Centre, Guildford, GU2 7YG
Telephone+44 1483685670
Websitehttps://www.futuramedical.com

Futura Medical PLC Advisors

AuditorKPMG
Phone+44 1189642000
Fax+44 1189642222
BankHSBC Bank PLC
SolicitorWithers & Rogers LLP
Phone+44 2079403600
Fax+44 2073789680
StockbrokerN+1 Singer
Phone+44 2074963000
Fax+44 2074963150
Nominated AdviserN+1 Singer
Phone+44 2074963000
Fax+44 2074963150
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserBuchanan
Phone+44 2074665000
Fax+44 2074665001
SolicitorMemery Crystal
Phone+44 2072425905
Fax+44 2072422058